Evidence map›Paper›PMID 27913621›Full record

ArticleThe Journal of biological chemistry2017

Identification of Hepatic Lysophosphatidylcholine Acyltransferase 3 as a Novel Target Gene Regulated by Peroxisome Proliferator-activated Receptor δ.

Amar Bahadur Singh, Jingwen Liu

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The interplay of miRNAs and ferroptosis in diseases related to iron overload.Apoptosis : an international journal on programmed cell death · 2024
    Review
  5. Article
  6. Overexpression ofAnimals : an open access journal from MDPI · 2023
    Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases.International journal of molecular sciences · 2019
    Review
  15. Phospholipid Remodeling in Physiology and Disease.Annual review of physiology · 2019
    Review
  16. Metabolites as regulators of insulin sensitivity and metabolism.Nature reviews. Molecular cell biology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amar Bahadur SinghFrom the Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304.
Jingwen LiuFrom the Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304 Jingwen.Liu@va.gov.
VA Palo Alto Health Care System · US

Funding

Targeting PCSK9 Transcription to Combat Hypercholesterolemia by BerberineR01AT006336 · NCCIH · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI LIU, JINGWEN · 2012 to 2016
$1.7M
Novel Cellular Mechanisms for Reducing HyperlipidemiaI01BX001419 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI KRAEMER, FREDRIC B. · 2012 to 2020
–
BLRD VA I01 BX001419NCCIH NIH HHS R01 AT006336
6 · The paper itself

Abstract

Peroxisome proliferator-activated receptor δ (PPARδ) regulates many genes involved in lipid metabolism. Hepatic lysophosphatidylcholine acyltransferase 3 (LPCAT3) has critical functions in triglycerides transport and endoplasmic reticulum stress response due to its unique ability to catalyze the incorporation of polyunsaturated fatty acids into phospholipids. Previous studies identified liver X receptor as the transcription factor controlling LPCAT3 expression in mouse liver tissue. Here we show that the hepatic LPCAT3 gene is transcriptionally regulated by PPARδ. Adenovirus-mediated knockdown of PPARδ in cultured hepatic cells and liver tissue reduced LPCAT3 mRNA levels, and exogenous overexpression of PPARδ increased LPCAT3 mRNA expression. Activation of PPARδ in HepG2, Huh7, and Hepa 1-6 cells with its specific agonists increased LPCAT3 mRNA levels in all three hepatic cell lines. Through conducting sequence analysis, LPCAT3 promoter assays, and direct DNA binding assays, we have mapped the functional PPAR-responsive element to a proximal region from -135 to -123 of the LPCAT3 promoter that plays an essential role in mediating PPARδ-induced transactivation of the LPCAT3 gene. Finally, we have provided in vivo evidence showing that activation of PPARδ by agonist L165041 in mice increased hepatic LPCAT3 mRNA abundance and LPCAT enzymatic activity, which is associated with increased incorporations of arachidonate into liver phosphatidylcholine and phosphatidylethanolamine. Furthermore, transient liver-specific knockdown of LPCAT3 in mice affected PPARδ-mediated activation of several hepatic genes involving in FA metabolism. Altogether, our new findings identify LPCAT3 as a direct PPARδ target gene and suggest a novel function of PPARδ in regulation of phospholipid metabolism through LPCAT3.

Indexed as

1-Acylglycerophosphocholine O-AcyltransferaseAnimalsFatty AcidsHep G2 CellsHumansLiverMicePhenoxyacetatesPhospholipidsPPAR deltaPromoter Regions, Genetic1-Acylglycerophosphocholine O-Acyltransferase4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acidFatty AcidsLPCAT3 protein, humanLPCAT3 protein, mousePhenoxyacetatesPhospholipidsPPAR deltagene regulationlipid metabolismliver metabolismperoxisome proliferator-activated receptor (PPAR)phospholipid

Identifiers

PMID27913621
PMCPMC5247661
OpenAlexW2559655734

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.